Triple-negative breast cancer (TNBC) remains clinically challenging due to the absence of hormone receptors and HER2, which limits effective targeted therapies. Dual inhibition of Focal adhesion kinase 1 (FAK1) and FAK2 has been proposed as a promising approach to impair signaling pathways that support tumor cell survival, proliferation, and metastasis. Given the limited structural diversity among existing dual FAK-targeted ligands and the potential therapeutic value of simultaneous FAK1/FAK2 inhibition in TNBC, the authors sought novel chemotypes that could engage both kinases.
Using structure-based virtual screening, the investigators identified a pyrazolo[3,4-b]pyridine scaffold as a candidate chemotype capable of dual engagement with FAK1 and FAK2. This scaffold was taken forward for chemical optimization to explore structure-activity relationships and generate derivatives for biochemical and cellular evaluation.
A set of 16 derivatives based on the pyrazolo[3,4-b]pyridine core was synthesized and screened. Among these, compound 8a demonstrated the strongest binding affinity to both kinases measured by dissociation constants (KD). Reported KD values for 8a were 2.9 μM for FAK1 and 2.5 μM for FAK2, indicating micromolar-range affinity for each target. The study prioritized 8a for downstream cellular and in vivo experiments because of its balanced dual-target binding and apparent selectivity toward TNBC cell models.
Cell-based target engagement studies indicated that 8a interacts with FAK1 and FAK2 inside cells. Specifically, treatment with 8a protected discrete peptides within the kinase domains of both FAK1 and FAK2, consistent with intracellular binding at or near the catalytic domains. These findings support that 8a engages its intended kinase targets in the cellular context rather than acting solely through off-target mechanisms.
Functionally, exposure to 8a induced cell-cycle perturbation characterized by G2/M-phase arrest. The compound also activated DNA damage–related signaling pathways and was associated with decreased phosphorylation of CDK1, a regulator of G2/M progression. Collectively, these observations suggest that 8a’s antiproliferative activity in TNBC cells involves induction of DNA damage signaling and disruption of cell-cycle control, in addition to direct kinase engagement.
The authors evaluated the dependence of 8a’s effects on FAK1/FAK2 expression by knockdown experiments. The antiproliferative activity of 8a was markedly attenuated when FAK1 and FAK2 were depleted, indicating that its efficacy is at least partially target-dependent. Conversely, combined treatment with doxorubicin markedly enhanced the antiproliferative effect of 8a, suggesting potential for combination regimens that leverage conventional chemotherapy with targeted dual-FAK inhibition.
In an in vivo 4 T1 tumor model, treatment with 8a inhibited tumor growth. The study reports that this antitumor activity occurred without significant body weight loss in treated animals, which the authors present as an initial indicator of tolerability. Detailed dosing schedules, pharmacokinetics, and broader safety assessments were not described in the abstract and require consultation of the full text for comprehensive evaluation.
This study identifies pyrazolo[3,4-b]pyridine as a novel chemotype for dual-targeting of FAK1/FAK2 and proposes compound 8a as a target-dependent lead compound for anti-TNBC drug development. Key translational findings include micromolar KD values for both kinases, intracellular target engagement, induction of G2/M arrest and DNA damage signaling, attenuation of activity after FAK1/FAK2 knockdown, synergy with doxorubicin, and in vivo tumor growth inhibition without marked weight loss.
Limitations and gaps reported in the abstract: the full structure-activity relationship details, complete experimental methods, dosing regimens, statistical analyses, comprehensive toxicity profiling, and broader selectivity panels are not presented in the abstract. Those details are necessary to fully assess the therapeutic potential and safety of 8a and should be consulted in the full text.
Overall, the findings support further preclinical development of the pyrazolo[3,4-b]pyridine chemotype and additional studies to define pharmacology, safety margins, and the optimal combination strategies for translation toward TNBC therapy.